Tokyo, March 20 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060988) titled 'A Patient and Family Questionnaire Survey on Satisfaction with Lecanemab Treatment and Its Related Factors' on March 20.
Study Type:
Observational
Primary Sponsor:
Institute - Eisai Co., Ltd.
Condition:
Condition - Early Alzheimer's Disease
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To investigate subjective satisfaction with lecanemab treatment among patients with early Alzheimer's disease and their family care partners in real-world clinical practice, and to identify factors influencing treatment satisfaction.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patient
1)First-time respondent to this study questionnaire
2)Diagnosed with early AD and initiated lecanemab treatment
3)At least 6 months have passed since lecanemab treatment initiation
4)Written informed consent obtained based on the patient's free will
5)Age 18 years or older
Family care partner
1)First-time respondent to this study questionnaire
2)Provides daily support or caregiving to an eligible patient
3)Written informed consent obtained
4)Age 18 years or older
Key exclusion criteria - Patient
Unable to complete the questionnaire by themselves or via designated family assistance
Family care partner
Unable to complete the questionnaire
Target Size - 120
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 03 Month 18 Day
Date of IRB - 2026 Year 03 Month 18 Day
Anticipated trial start date - 2026 Year 03 Month 30 Day
Last follow-up date - 2026 Year 06 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069787
Disclaimer: Curated by HT Syndication.
